News for Kissei Pharmaceutical Co., Ltd. (4547.T)

PR NewswireSOUTH SAN FRANCISCO, Calif., March 4, 2025 Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net prod

The market for medications for chronic kidney disease (CKD) is growing due to an increase in the prevalence of CKD....

Cancer drug company CG Oncology Inc. priced its initial public offering above its estimated range and added three million shares to the deal in a bullish...

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for…

Cara Therapeutics, Inc. (CARA), a commercial-stage biopharmaceutical company focused on pruritus, announced Monday the Approval of KORSUVA IV Injection Syringe in Japan to treat pruritus in hemodialysis patients.

Approval triggers $1.5 million milestone payment to Cara...

Newark, New Castle, USA, May 26, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports estimated the size of the global market for adrenoblockers in 2022 and is...

The prevalence of mesothelioma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence...

Parkinson's disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which...

Newark, New Castle, USA, March 16, 2023 (GLOBE NEWSWIRE) -- According to the deep-dive market assessment study by Growth Plus Reports, the global chronic...

/PRNewswire/ -- The

The fast melt tablets market is experiencing rapid growth and is projected to continue expanding in the coming years. SkyQuest's research report is a...

Seattle, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global chronic kidney disease drugs market is estimated to be...

Around 6+ key companies are developing Uremic Pruritus therapies. The drug candidate Difelikefalin by Cara Therapeutics has been accepted and granted...